Clinical Trials Sponsored by Hutchison Medipharma Limited

Total 134 results

Hutchison Medipharma Limited

Completed

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Tumors

United States, Italy
Hutchison Medipharma Limited

Active, not recruiting

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA)

Warm Antibody Autoimmune Hemolytic Anemia

China
Hutchison Medipharma Limited

Completed

Surufatinib Hepatic Impairment Study

Hepatic Impairment

United States
Hutchison Medipharma Limited

Active, not recruiting

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Lung Sarcomatoid Carcinoma

China
Hutchison Medipharma Limited

Completed

A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

Healthy

United States
Hutchison Medipharma Limited

Unknown

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Biliary Tract Cancer

China
Hutchison Medipharma Limited

Terminated

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Hutchison Medipharma Limited

Completed

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

NSCLC

China
Hutchison Medipharma Limited

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumors

China
Hutchison Medipharma Limited

Completed

A Food Effect Phase I Study of the Volitinib in Healthy Subjects (HMPL-504)

Food Effect | Health Subjects

China
Hutchison Medipharma Limited

Completed

Phase I Clinical Trial in Healthy Male Volunteers

Inflammatory Bowel Diseases
Hutchison Medipharma Limited

Terminated

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor (HMPL-309)

Cancer

China
Hutchison Medipharma Limited

Completed

To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers (CRC-C1721)

Relative Bioavailability

China
Hutchison Medipharma Limited

Completed

A Study of HMPL-689 in Healthy Volunteers

Healthy Volunteers

Australia
Hutchison Medipharma Limited
AstraZeneca

Completed

A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Hutchison Medipharma Limited
BeiGene

Active, not recruiting

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Colorectal Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Solid Tumor, Unspecified, Adult

United States
Hutchison Medipharma Limited
Covance

Completed

Fruquintinib CYP3A Inhibitor and Inducer Study

Drug Drug Interaction

United States
Hutchison Medipharma Limited
AstraZeneca

Completed

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Non-Small Cell Lung Cancer

China
Hutchison Medipharma Limited
Nutrition Science Partners Limited

Terminated

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis (NATRUL-4)

Ulcerative Colitis

United States
Hunan Cancer Hospital
Hutchison Medipharma Limited

Not yet recruiting

Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
Hutchison Medipharma Limited
Fudan University

Completed

Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

Tumor

China
Nutrition Science Partners Limited
Hutchison Medipharma Limited; Nestlé

Terminated

HMPL004-6599 Phase I Dose-escalating Study

Crohn Disease | Ulcerative Colitis

Australia
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Metastatic Non-small Cell Lung Cancer

China
Genor Biopharma Co., Ltd.
Hutchison Medipharma Limited

Unknown

Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Chinese PLA General Hospital
Hutchison Medipharma Limited

Recruiting

Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Hutchison Medipharma Limited
Iqvia Pty Ltd

Unknown

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancies

Australia
Hutchison Medipharma Limited
Shanghai Chest Hospital

Completed

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
AstraZeneca
Hutchison MediPharma

Recruiting

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

Carcinoma

Denmark, Spain, United States, Taiwan, Vietnam, Canada, Korea, Republic of, Brazil, India, Japan, Italy, Puerto Rico, France, Chile
Hutchison Medipharma Limited
Sun Yat-sen University

Active, not recruiting

A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (FRUTIGA)

Advanced Gastric Cancer

China
AstraZeneca
Hutchinson MediPharma (HMP)

Active, not recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Neoplasms by Site | Kidney Diseases | Carcinoma | Enzyme Inhibitors | Protein Kinase Inhibitors

United States, Italy, France, Korea, Republic of, Brazil, Russian Federation, Ukraine
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Colorectal Cancer

China
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

China
Mundipharma Research Limited

Active, not recruiting

Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

Glioblastoma Multiforme

Switzerland, Spain
Mundipharma Research Limited

Completed

A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD

Chronic Obstructive Pulmonary Disease

Ukraine, United Kingdom, Spain, Bulgaria, South Africa, Russian Federation, Germany, Hungary, Lithuania, Slovakia, Macedonia, The Former Yugoslav Republic of, Latvia, Romania, Korea, Republic of, Poland
Mundipharma Research Limited

Completed

Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.

Mild Persistent Asthma

Denmark
Mundipharma Research Limited

Terminated

A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils

ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)

Slovakia
Mundipharma Research Limited

Completed

Bioequivalence and Adhesion Comparison of Buprenorphine Patches

Pain

United Kingdom
Mundipharma Research Limited

Completed

A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers

Asthma

United Kingdom
Mundipharma Research Limited

Completed

A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches

Pain

United Kingdom
Mundipharma Research Limited

Recruiting

Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

Pneumocystis Pneumonia

South Africa
Mundipharma Research Limited

Recruiting

Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

Invasive Fungal Infections

Spain, United Kingdom, Germany
Mundipharma Research Limited

Active, not recruiting

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Hematological Malignancies | Cutaneous T Cell Lymphoma

France, United States, Netherlands, Spain, Switzerland, Germany, Italy
Mundipharma Research Limited

Completed

An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma

Asthma Bronchiale

Poland, Romania, Netherlands, United Kingdom, Germany, Hungary
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
Mundipharma Research Limited

Completed

Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients

Asthma

Russian Federation, Ukraine, Bulgaria, Czechia, Hungary, India, Poland, Romania
Mundipharma Research Limited

Completed

Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma

Asthma

Romania, Hungary, Czechia, France, Germany, Poland
Mundipharma Research Limited

Completed

Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma (FLT2503)

Asthma

Germany
Mundipharma Research Limited

Terminated

A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab. (ROBIN)

Indolent B-cell NHL

Australia, Slovakia
Mundipharma Research Limited

Completed

A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication

Pain

United Kingdom
Mundipharma Research Limited

Completed

Flutiform® Compared With Seretide® in the Treatment of COPD

Chronic Obstructive Pulmonary Disease

China, Taiwan, Korea, Republic of, New Zealand, Australia

Clinical Trials Sponsored by Hutchison Medipharma Limited

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations